EXACT Sciences Corporation Stock News

Exact Sciences' (EXAS) first-quarter 2024 performance is expected to include gains from robust Cologuard uptake and continuing Oncotype DX growth, offset slightly by increasing operating costs.

Exact Sciences (EXAS) concluded the recent trading session at $63.22, signifying a -1% move from its prior day's close.

While the market has taken a small breather as of late, there have been many big-time winners throughout the last month, including these three. Analysts are bullish on their outlooks, with all three c

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, will present late-breaking data from the first analysis of the ASCEND-

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its first quarter 20

Full disclosure, I'm not a tremendous fan of Cathie Wood. Generally, I think she makes some terrible picks.

Exact Sciences' most important product is still driving top-line growth. The company is working on several other exciting diagnostic tests.

Exact Sciences (EXAS) advances the development of the non-endoscopic Oncoguard Esophagus test to screen for esophageal cancer and pre-cancer.

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

The mean of analysts' price targets for Exact Sciences (EXAS) points to a 53.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among a

Exact Sciences (EXAS) reported earnings 30 days ago. What's next for the stock?

Exact Sciences (EXAS) announces the publication of the BLUE-C study results in The New England Journal of Medicine.

The consensus price target hints at a 55.4% upside potential for Exact Sciences (EXAS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings es

We have narrowed our search to five biotech stocks with strong potential for 2024. These are MOR, LEGN, ASND, EXEL and EXAS.

Healthcare stocks have started the year off very strongly, propelled by excitement about weight loss drugs and investments by Nvidia (NASDAQ: NVDA ). The sector is also getting a lift from the U.S. Fe